Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection

Melanoma Research

Volumn 18, Issue 1, 2008, Pages 16-21

  Kretschmer, Lutz ^a   Thoms, Kai Martin ^a   Peeters, Sabine ^b   Haenssle, Holger ^a   Bertsch, Hans Peter ^a   Emmert, Steffen ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Clinic of Krefeld   (Germany)

Author keywords

Lymph node excision; Melanoma; Morbidity; Sentinel

Indexed keywords

CEFAZOLIN; ENOXAPARIN;

ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; GERIATRIC PATIENT; HEMATOMA; HUMAN; LYMPH NODE DISSECTION; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; MORBIDITY; NEUROPATHY; PAIN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUESTIONNAIRE; SENTINEL LYMPH NODE; SEROMA; SINGLE DRUG DOSE; SWELLING; TATTOOING; THROMBOSIS; WOUND INFECTION; FEMALE; FOLLOW UP; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE PERIOD; SENTINEL LYMPH NODE BIOPSY; SKIN TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; POSTOPERATIVE PERIOD; QUESTIONNAIRES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 42449116716     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3282f2017d     Document Type: Article

References (34)

1. Lee JH, Essner R, Torisu-Itakura H, Wanek L, Wang H, Morton DL. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol 2004; 22:3677-3684.
2. Kretschmer L, Preusser KP. Standardized axillary lymphadenectomy improves local control but not survival in patients with palpable lymph node metastases of cutaneous malignant melanoma. Langenbecks Arch Surg 2001; 386:418-425.
3. Kretschmer L, Neumann CH, Preusser K-P, Marsch WCH. Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin: an analysis of survival and local recurrence. Acta Oncol 2001; 40:72-78.
4. Baas PC, Schraffordt KH, Hoekstra HJ, van Bruggen JJ, van der Weele LT, Oldhoff J. Groin dissection in the treatment of lower-extremity melanoma. Short-term and long-term morbidity. Arch Surg 1992; 127:281-286.
5. Jansen L, Nieweg OE, Peterse JL, Hoefnagel CA, Olmos RA, Kroon BB. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg 2000; 87:484-489.
6. Blumenthal R, Banic A, Brand CU, Ris HB, Lardinois D. Morbidity and outcome after sentinel lymph node dissection in patients with early-stage malignant cutaneous melanoma. Swiss Surg 2002; 8:209-214.
7. Wrightson WR, Wong SL, Edwards MJ, Chao C, Reintgen DS, Ross MI, et al., Sunbelt Melanoma Trial Study Group. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol 2003; 10:676-680.
8. Serpell JW, Carne PW, Bailey M. Radical lymph node dissection for melanoma. ANZ J Surg 2003; 73:294-299.
9. Wasserberg N, Tulchinsky H, Schachter J, Feinmesser M, Gutman H. Sentinel-lymph-node biopsy (SLNB) for melanoma is not complication-free. Eur J Surg Oncol 2004; 30:851-856.
10. Roaten JB, Pearlman N, Gonzalez R, Gonzalez R, McCarter MD. Identifying risk factors for complications following sentinel lymph node biopsy for melanoma. Arch Surg 2005; 140:85-89.
11. De Vries M, Vonkeman WG, van Ginkel RJ, Hoekstra HJ. Morbidity after axillary sentinel lymph node biopsy in patients with cutaneous melanoma. Eur J Surg Oncol 2005; 31:778-783.
12. Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, et al., Multicenter Selective Lymphadenectomy Trial Group. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005; 242:302-311.
13. Kretschmer L, Peeters S, Beckmann I, Thoms KM, Mitteldorf C, Emmert S, et al. Intraoperative detection of sentinel lymph nodes in cutaneous malignant melanoma: blue dye alone vs. blue dye plus gamma detection. J Dtsch Dermatol Ges 2005; 3:615-622.
14. Urist MM, Maddox WA, Kennedy JE, Balch CM. Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients. Cancer 1983; 51:2152-2156.
15. Karakousis CP, Goumas W, Rao U, Driscoll DL. Axillary node dissection in malignant melanoma. Am J Surg 1991; 162:202-207.
16. Shaw JH, Rumball EM. Complications and local recurrence following lymphadenectomy. Br J Surg 1990; 77:760-764.
17. Starritt EC, Joseph D, McKinnon JG, Lo SK, de Wilt JH, Thompson JF. Lymphedema after complete axillary node dissection for melanoma: assessment using a new, objective definition. Ann Surg 2004; 240:866-874.
18. Bowsher WG, Taylor BA, Hughes LE. Morbidity, mortality and local recurrence following regional node dissection for melanoma. Br J Surg 1986; 73:906-908.
19. Kissin MW, Simpson DA, Easton D, White H, Westbury G. Prognostic factors related to survival and groin recurrence following therapeutic lymph node dissection for lower limb malignant melanoma. Br J Surg 1987; 74:1023-1026.
20. Zoltie N, Chapman P, Joss G. Is iliac node clearance necessary for stage II melanoma? Plast Reconstr Surg 1991; 88:810-813.
21. Beitsch P, Balch C. Operative morbidity and risk factor assessment in melanoma patients undergoing inguinal lymph node dissection. Am J Surg 1992; 164:462-465.
22. Sterne GD, Murray DS, Grimlley RP. Ilioinguinal block dissection for malignant melanoma. Br J Surg 1995; 82:1057-1059.
23. Karakousis CP, Driscoll DL. Groin dissection in malignant melanoma. Br J Surg 1994; 81:1771-1774.
24. Kretschmer L, Altenvoerde G, Meller J, Zutt M, Funke M, Neumann C, Becker W. Dynamic lymphoscintigraphy and image fusion of SPECT and pelvic CT-scans allow mapping of aberrant pelvic sentinel lymph nodes in malignant melanoma. Eur J Cancer 2003; 39:175-183.
25. Hughes TM, A'Hern RP, Thomas JM. Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma. Br J Surg 2000; 87:892-901.
26. Coit DG, Peters M, Brennan MF. A prospective randomized trial of perioperative cefazolin treatment in axillary and groin dissection. Arch Surg 1991; 126:1366-1371.
27. Bold RJ, Mansfield PF, Berger DH, Pollock RE, Singletary SE, Ames FC, et al. Prospective, randomized, double-blind study of prophylactic antibiotics in axillary lymph node dissection. Am J Surg 1998; 176:239-243.
28. Karakousis CP. Therapeutic node dissections in malignant melanoma. Ann Surg Oncol 1998; 5:473-482.
29. Fleissig A, Fallowfield LJ, Langridge CI, Johnson L, Newcombe RG, Dixon JM, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 2005; 15:1-15.
30. Kane M, McClay E, Bellet RE. Frequency of occult residual melanoma after excision of a clinically positive regional lymph node. Ann Surg 1987; 205:88-89.
31. Karakousis CP, Rizos S, Driscoll DL. Residual nodal disease after excisional biopsy of a palpable, positive node in melanoma. Am J Surg 1994; 168:69-70.
32. Meyer T, Merkel S, Gohl J, Hohenberger W. Lymph node dissection for clinically evident lymph node metastases of malignant melanoma. Eur J Surg Oncol 2002; 28:424-430.
33. Morton DL, Thompson JF, Cochran AJ, Essner R, Elashoff R. Interim results of the Multicenter Selective Lymphadenectomy Trial (MSLT-I) in clinical stage I melanoma [meeting abstracts]. J Clin Oncol 2005; 23 (Suppl 16):7500.
34. Kretschmer L, Hilgers R, Möhrle M, Balda BR, Breuninger H, Konz B, et al. Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer 2004; 40:212-218.